Brentuximab vedotin (BV) versus physician's choice (PC) of methotrexate or bexarotene in adult patients with previously treated CD30-positive cutaneous T-cell lymphoma (CTCL; mycosis fungoides [MF] or primary cutaneous anaplastic large cell lymphoma [pcALCL]): final time to next therapy (TTNT) results from the phase 3 ALCANZA study. (2019) - Scarisbrick, Julia; Horwitz, Steven M.; Prince, H. Miles; Whittaker, Sean; Duvic, Madeleine; Kim, Youn H.; Quaglino, Pietro; Zinzani, Pier Luigi; Bechter, Oliver; Eradat, Herbert; Pinter-Brown, Lauren; Akilov, Oleg; et al.